Wir sind jetzt auf verfügbar! Mehr erfahren
KTTAW-Logo

Pasithea Therapeutics Warrants
KTTAW

Nicht mehr börsennotiert

KTTAW wurde am 15. September 2026 von der Börse genommen.

 

Profil: Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Mitarbeiter: 5

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 0 %
Neutral 0 %
Negativ 0 %

Für KTTAW liegen uns keine aktuellen Nachrichtenartikel vor.

Kursdiagramme mit Lightweight Charts™ umgesetzt